Patents Assigned to Active Biotech AB
-
Publication number: 20130123301Abstract: A stable solid pharmaceutical composition consisting essentially of an effective amount of a crystalline salt of formula (II) together with an alkaline-reacting component maintaining the pH preferably above 8, or a salt with a divalent metal cation; and at least one pharmaceutical excipient; to said salt of formula (II) being essentially stable during storage at room temperature for a period of at least 3 years. A process for stabilizing the salt of formula (II). A crystalline salt of formula (II) and a process for preparing said salt.Type: ApplicationFiled: November 6, 2012Publication date: May 16, 2013Applicant: ACTIVE BIOTECH ABInventor: Active Biotech AB
-
Publication number: 20130109860Abstract: A method for preparing a compound of formula (I) by reacting the appropriate alkyl ester and an aniline derivative, in a refluxing mixture containing an aliphatic solvent or a mixture of aliphatic solvents having a boiling point in the range of 68-191° C.; condensing vapors of the refluxing mixture; treating the condensed vapors with an alcohol scavenging agent or a mixture of alcohol scavenging agents; and returning the condensed vapors back to the reaction mixture.Type: ApplicationFiled: July 7, 2011Publication date: May 2, 2013Applicant: ACTIVE BIOTECH ABInventors: Lillemor Maria Bock, Par Henning Holmberg, Karl-Erik Jansson
-
Patent number: 8314124Abstract: A stable solid pharmaceutical composition consisting essentially of an effective amount of a crystalline salt of formula (II) together with an alkaline-reacting component maintaining the pH preferably above 8, or a salt with a divalent metal cation; and at least one pharmaceutical excipient; said salt of formula (II) being essentially stable during storage at room temperature for a period of at least 3 years. A process for stabilizing the salt of formula (II). A crystalline salt of formula (II) and a process for preparing said salt.Type: GrantFiled: March 17, 2009Date of Patent: November 20, 2012Assignee: Active Biotech ABInventors: Karl Jansson, Tomas Fristedt, Hans Wännman, Anders Björk
-
Patent number: 8293243Abstract: The present invention relates to methods of treating mammals affected by, for example, a hyperproliferative disease such as cancer, by administering a tumor-targeted superantigen and a chemotherapeutic agent, whereby the administration of the tumor-targeted superantigen and chemotherapeutic agent reduce the antibody response and enhance the T cell response. The superantigen, wild-type or modified, is fused to a target-seeking moiety, such as an antibody or an antibody active fragment. The combined administration of a superantigen and a chemotherapeutic agent provides enhanced therapeutic effects in a treated animal.Type: GrantFiled: May 25, 2010Date of Patent: October 23, 2012Assignee: Active Biotech ABInventors: Gunnar Hedlund, Göran Forsberg, Marie Wallén-öhman
-
Patent number: 7763253Abstract: The present invention relates to methods of treating mammals affected by, for example, a hyperproliferative disease such as cancer, by administering a tumor-targeted superantigen and a chemotherapeutic agent, whereby the administration of the tumor-targeted superantigen and chemotherapeutic agent reduce the antibody response and enhance the T cell response. The superantigen, wild-type or modified, is fused to a target-seeking moiety, such as an antibody or an antibody active fragment. The combined administration of a superantigen and a chemotherapeutic agent provides enhanced therapeutic effects in a treated animal.Type: GrantFiled: August 12, 2005Date of Patent: July 27, 2010Assignee: Active Biotech, ABInventors: Gunnar Hedlund, Göran Forsberg, Marie Wallén-öhman
-
Publication number: 20100166775Abstract: A method of identifying a compound for use in therapy which modulates the interaction of S1OO A9 with a ligand comprising: -determining whether a candidate compound is capable of modulating the interaction of S1OO A9 with RAGE or the interaction of S1OO A9 with a TLR (Toll like receptor), or -determining whether a candidate compound is capable of binding to S100A9 in a manner which disrupts binding of S1OO A9 with RAGE or the binding of S100A9 with a TLR, to thereby identify whether the compound may be used in therapy.Type: ApplicationFiled: April 24, 2008Publication date: July 1, 2010Applicant: Active Biotech, ABInventors: Per Bjork, Fredrik Ivars, Tomas Leanderson
-
Publication number: 20100111978Abstract: The present invention relates to compositions and methods of use, wherein the composition comprises a conjugate of a bacterial superantigen and an antibody moiety. More particularly, the bacterial superantigen has been modified to decrease seroreactivity with retained superantigen activity.Type: ApplicationFiled: September 28, 2009Publication date: May 6, 2010Applicant: ACTIVE BIOTECH ABInventors: GORAN FORSBERG, EVA ERLANDSSON, PER ANTONSSON, BJORN WALSE
-
Patent number: 7674906Abstract: The present invention relates to novel heterocyclic compounds, to methods for their preparation, to compositions containing them, and to methods and use for clinical treatment of medical conditions which may benefit from immunomodulation, including rheumatoid arthritis, multiple sclerosis, diabetes, asthma, transplantation, systemic lupus erythematosis and psoriasis. More particularly, the present invention relates to novel heterocyclic compounds, which are CD80 antagonists capable of inhibiting the interactions between CD80 and CD28.Type: GrantFiled: December 12, 2003Date of Patent: March 9, 2010Assignee: Active Biotech ABInventors: Ian Richard Matthews, Philip Huxley, Filippo Magaraci, Chris James Brennan, Muhammed Kamal Uddin, Lars Olof Göran Pettersson, Dorthe da Graca Thrige
-
Patent number: 7615225Abstract: The present invention relates to compositions and methods of use, wherein the composition comprises a conjugate of a bacterial superantigen and an antibody moiety. More particularly, the bacterial superantigen has been modified to decrease seroreactivity with retained superantigen activity.Type: GrantFiled: September 25, 2006Date of Patent: November 10, 2009Assignee: Active Biotech ABInventors: Goran Forsberg, Eva Erlandsson, Per Antonsson, Bjorn Walse
-
Publication number: 20090232889Abstract: A stable solid pharmaceutical composition consisting essentially of an effective amount of a crystalline salt of formula (II) together with an alkaline-reacting component maintaining the pH preferably above 8, or a salt with a divalent metal cation; and at least one pharmaceutical excipient; said salt of formula (II) being essentially stable during storage at room temperature for a period of at least 3 years. A process for stabilizing the salt of formula (II). A crystalline salt of formula (II) and a process for preparing said salt.Type: ApplicationFiled: March 17, 2009Publication date: September 17, 2009Applicant: Active Biotech ABInventors: Karl Jansson, Tomas Fristedt, Hans Wannman, Anders Bjork
-
Patent number: 7589208Abstract: A stable solid pharmaceutical composition consisting essentially of an effective amount of a salt of formula (II) together with an alkaline-reacting component maintaining the pH preferably above 8, or a salt with a divalent metal cation; and at least one pharmaceutical excipient; said salt of formula (II) being essentially stable during storage at room temperature for a period of at least 3 years. A process for stabilizing the salt of formula (II). A crystalline salt of formula (II) and a process for preparing said salt.Type: GrantFiled: February 4, 2005Date of Patent: September 15, 2009Assignee: Active Biotech ABInventors: Karl Jansson, Tomas Fristedt, Hans Wännman, Anders Björk
-
Patent number: 7553849Abstract: A compound of formula (I) wherein R is methyl, ethyl, n-propyl, iso-propyl, n-butyl or allyl; R? is hydrogen, C1-C4 alkyl, C1-C3 alkoxy; halogen, trifluoromethyl or OCHxFy, R? is hydrogen, fluoro or chloro, that R? being fluoro or chloro only when R? is fluoro or chloro; R3 is hydrogen or C1-C5 alkyl R4 is hydrogen, CH2OCOC(CH3)3, pharmaceutically acceptable inorganic or organic cations, or COR4? wherein R4? is C1-C5 alkyl, phenyl, benzyl or phenethyl; R7 is methyl or ethyl; one of A and B is sulphur and the other is C-R2; when A is S, R2 is selected from hydrogen and methyl, with the proviso that R2 is methyl only when R3 is not hydrogen; and when B is S, R2 is hydrogen; and any tautomer thereof. A pharmaceutical composition comprising a compound of formula (I), a method of treating malignant tumours or diseases resulting from autoimmunity or pathologic inflammation.Type: GrantFiled: June 15, 2005Date of Patent: June 30, 2009Assignee: Active Biotech ABInventors: Anders Björk, Karl Jansson
-
Patent number: 7511143Abstract: A stable solid pharmaceutical composition consisting essentially of an effective amount of a salt of formula (II) together with an alkaline-reacting component maintaining the pH preferably above 8, or a salt with a divalent metal cation; and at least one pharmaceutical excipient; said salt of formula (II) being essentially stable during storage at room temperature for a period of at least 3 years. A process for stabilizing the salt of formula (II). A crystalline salt of formula (II) and a process for preparing said salt.Type: GrantFiled: February 4, 2005Date of Patent: March 31, 2009Assignee: Active Biotech ABInventors: Karl Jansson, Tomas Fristedt, Hans Wännman, Anders Björk
-
Patent number: 7425623Abstract: A binding structure which binds in, and/or to the surface of, tumour cells; a target structure displayed and/or expressed in, or on the surface of, tumour cells; a binding structure that recognises and blocks said target structure; a substance that binds to or blocks the expression of said target structure; pharmaceutical compositions comprising said binding structure, target structures or substance as active principles; vaccine compositions comprising said target structures as active principles; a method for phage selection; and methods of in vitro and in vivo diagnosis and prognosis, and of treatment of human malignant diseases comprising the use of the above subject matters, are described.Type: GrantFiled: February 23, 2001Date of Patent: September 16, 2008Assignee: Active Biotech ABInventors: Thomas N. Brodin, Pia J. Karlström, Lennart G Ohlsson, Jesper M Tordsson, Bo H K. Nilson
-
Publication number: 20080119485Abstract: Compounds of formula (I) wherein X is a fluorine or a chlorine atom; the methyl groups located at the 2- and 5-position of the piperazine ring are in trans-configuration to each other; Y is NH or O; R1 is selected from hydrogen, chloro, bromo, nitro, methyl or trifluoromethyl; R2 is selected from hydrogen, halo, methyl, trifluoromethyl, methoxy or trifluoromethoxy; or a pharmaceutically acceptable salt or solvate thereof; The invention also relates to pharmaceutical compositions containing a compound of formula (I) together with a pharmaceutically acceptable carrier. Included are also processes for the preparation of compounds of formula (I), as well as methods for treating mammals suffering from inflammatory, autoimmune, proliferative or hyperproliferative diseases by administering a compound having the formula (I) to said mammal.Type: ApplicationFiled: January 23, 2008Publication date: May 22, 2008Applicant: Active Biotech ABInventors: Eric WELLNER, Helena Sandin
-
Patent number: 7339059Abstract: Compounds of formula (I) wherein X is a fluorine or a chlorine atom; the methyl groups located at the 2- and 5-position of the piperazine ring are in trans-configuration to each other; Y is NH or O; R1 is selected from hydrogen, chloro, bromo, nitro, methyl or trifluoromethyl; R2 is selected from hydrogen, halo, methyl, trifluoromethyl, methoxy or trifluoromethoxy; or a pharmaceutically acceptable salt or solvate thereof; The invention also relates to pharmaceutical compositions containing a compound of formula (I) together with a pharmaceutically acceptable carrier. Included are also processes for the preparation of compounds of formula (I), as well as methods for treating mammals suffering from inflammatory, autoimmune, proliferative or hyperproliferative diseases by administering a compound having the formula (I) to said mammal.Type: GrantFiled: November 23, 2004Date of Patent: March 4, 2008Assignee: Active Biotech ABInventors: Eric Wellner, Helena Sandin
-
Conjugate between a modified superantigen and a target-seeking compound and the use of the conjugate
Patent number: 7226601Abstract: A method for the treatment of a disease in a mammal by administering a therapeutically effective amount of a conjugate comprising a biospecific affinity counterpart and a peptide, wherein the peptide contains an amino acid sequence that is derived from staphylococcal enterotoxin A, binds to a V? of a T cell receptor, and has a D227A mutation so that the peptide has a modified ability to bind to MHC class II antigens.Type: GrantFiled: June 7, 1995Date of Patent: June 5, 2007Assignee: Active Biotech ABInventors: Lars Abrahmsen, Per Bjork, Mikael Dohlsten, Terje Kalland -
Publication number: 20070112179Abstract: An antibody, or a derivate or a fragment thereof, having a binding structure for a target structure is described. The antibody is displayed in, and on the cell surface of, human gastrointestinal epithelial tumour cells and in a subpopulation of normal human gastrointestinal epithelial cells. Said binding structure comprises the complementarity determining region (CDR) sequences in the light chain comprising essentially the amino acids number 23-33 (CDR1), 49-55 (CDR2), 88-98 (CDR3) of the amino acid sequence shown in SEQ ID NO:2, and the CDR sequences in the heavy chain comprising essentially the amino acids number 158-162 (CDR1), 177-193 (CDR2, 226-238 (CDR3) of the amino acid sequence shown in SEQ ID NO:2, or other binding structures with similar unique binding properties. There is also described a target structure displayed in, or on the surface of tumour cells, vaccine compositions, pharmaceutical compositions as well as methods related to human malignant diseases.Type: ApplicationFiled: November 8, 2006Publication date: May 17, 2007Applicant: ACTIVE BIOTECH ABInventors: Thomas Brodin, Pia Karlstrom, Lennart Ohlsson, Jesper Tordsson, Philip Kearney, Bo Nilson
-
Publication number: 20070082001Abstract: The present invention relates to compositions and methods of use, wherein the composition comprises a conjugate of a bacterial superantigen and an antibody moiety. More particularly, the bacterial superantigen has been modified to decrease seroreactivity with retained superantigen activity.Type: ApplicationFiled: November 21, 2006Publication date: April 12, 2007Applicant: ACTIVE BIOTECH ABInventors: Goran Forsberg, Eva Erlandsson, Per Antonsson, Bjorn Walse
-
Patent number: 7189816Abstract: An antibody, or a derivate or a fragment thereof, having a binding structure for a target structure is described. The antibody is displayed in, and on the cell surface of, human gastrointestinal epithelial tumour cells and in a subpopulation of normal human gastrointestinal epithelial cells. Said binding structure comprises the complementarity determining region (CDR) sequences in the light chain comprising essentially the amino acids number 23–33 (CDR1), 49–55 (CDR2), 88–98 (CDR3) of the amino acid sequence shown in SEQ ID NO:2, and the CDR sequences in the heavy chain comprising essentially the amino acids number 158–162 (CDR1), 177–193 (CDR2, 226–238 (CDR3) of the amino acid sequence shown in SEQ ID NO:2, or other binding structures with similar unique binding properties. There is also described a target structure displayed in, or on the surface of tumour cells, vaccine compositions, pharmaceutical compositions as well as methods related to human malignant diseases.Type: GrantFiled: October 26, 2000Date of Patent: March 13, 2007Assignee: Active Biotech ABInventors: Thomas Brodin, Pia J. Karlström, Lennart G. Ohlsson, Jesper M. Tordsson, Philip P. Kearney, Bo H. K. Nilson